Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL I love that post.
Posted by: jjtruthmatters
In reply to: IH Admin [Matt] who wrote msg# 84473 Date:1/1/2007 3:55:41 PM
Post #of 86210
Matt, please can I get out of jail? My new year's resolution is to never post from multiple accounts again.
I'm far more interested in learning from traders such as penny_ta, fringe_remnant, and Jim Bishop.
I promise you will have no more problems from me. I previously used my IHUB account as an outlet for continuously losing money on penny stocks while others pumped and pumped. I hope to build to be part of the honest investor community.
Thanks for your consideration of my request.
and I thought you were slacking due to no 10 bagger in a couple days..YOU STILL DA MAN THANKS SSP
I am not really expecting an answer while this is in play, just how far can this go..once they have to cover the shorted shares..
IS it better to hold DEXTQ of flip it?
EXEGENICS INC COM (EXEG: OTC BB) Institutional Holdings SummaryTotal Number of Shares Held 20,349,640
Large Block Owners 11
Percent Shares Owned 55.70%
Percent Change in Ownership --
Regional Holdings
North America 53.10%
Unknown 2.60%
Europe 0.00%
Investment Managers
3.20% Holdings
Strategic Entities
52.50% Holdings
Non-Institutional
44.30% Holding
Top Institutional OwnersConcentration of Shares Held 55.70% All Institutions 44.30% Other Owners
55.70% Top 50
55.70% Top 20
55.70% Top 10
Average Turnover Rating
Name Shares Held Position Value % of Total Holdings % Owned of Outstanding Shares Turnover Rating
Baron (Robert A) 71,800 $57,440 0.35% 0.09% Moderate
Benou (Robert) 25,000 $20,000 0.12% 0.03% Low
D. H. Blair Investment Bank Corpora... 359,400 $359,400 1.77% 0.56% Low
David M. Knott Partnership 815,800 $815,800 4.01% 1.26% Low
Frost Group, L.L.C. 15,490,546 $33,614,485 76.12% 52.06% Moderate
Meyers (Bruce) 326,092 $260,874 1.60% 0.40% Moderate
Meyers Associates, L.P. 76,092 $60,874 0.37% 0.09% High
Paganelli (John A) 100,000 $217,000 0.49% 0.34% Low
Spencer (David Lee) 799,100 $639,280 3.93% 0.99% Low
Vector Group Ltd. 2,257,110 $4,897,929 11.09% 7.59% N/A
Top Mutual Fund OwnersPercentage of Outstanding Shares per Holdings Style
0.03% International
Average Turnover Rating
Name Shares Held Position Value % of Total Holdings % Owned of Outstanding Shares Investment Style
DWS Austria Pharma 7,000 $5,600 0.03% 0.01% International
YOU ARE...LOL
YES, and for $35.00 at close to take out the 0.007's and get the ask back to 0.008 any news this flys..if 0.003 before that I'll buy more..
Great close, someone dumped there shares but it came right back...
LOL..WOW lets get to $5.00 first..I thought my dollar jumps were a bit much..OH WELL COME ON $100.00 by close lol
I remember that day, I put an order in after your post, but when I checked later the order was rejected..LOL
Nothing stopping it now $5.00 NEXT!!
EXEG 4.00 x 4.00 up 23%
BINGO $4.00
Just placed a buy order for SIGN 10K at 0.0001 Etrade
EXEG looks great, no telling how far this could go.I've been in this since the $1.70 range.I don't think any chart guy could find a problem with EXEG chart. And yes it should be an easy uplisting to AMEX with Dr Frost on the board..LOL
Dr. Phillip Frost Member of the Board of Governors
American Stock Exchange LLC http://www.zoominfo.com/Search/PersonDetail.aspx?PersonID=448986 Dr Phillip Frost ranked 283 among The 400 Richest Americans In 2005. http://www.forbes.com/lists/2005/54/RT14.html
Acuity Pharmaceuticals News from The BioSpace Beat
Ownership: Private
Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye
MIAMI, March 27 /PRNewswire-FirstCall/ -- Acuity Pharmaceuticals and Froptix Corporation, privately owned pharmaceutical companies developing novel drugs to treat serious diseases of the eye, and eXegenics, Inc. , a publicly-traded company with no active operations, have executed a merger agreement that will bring the three companies under one corporate umbrella. The combined company will be re-named Opko Corporation. It will be headquartered in Miami, Florida and intends to apply to have its shares listed on the American Stock Exchange (AMEX).
(See Story from BioSpace.com) (03/27/2007)
Acuity Pharmaceuticals Appoints Denis O'Shaughnessy Senior Vice President Of Clinical Development
PHILADELPHIA, Oct. 24 /PRNewswire/ -- Acuity Pharmaceuticals, a clinical stage ophthalmic pharmaceutical company, today announced the appointment of Denis O'Shaughnessy, Ph.D., as senior vice president of clinical development. Dr. O'Shaughnessy was formerly the senior vice president of clinical development and a founding member of Eyetech Pharmaceuticals, Inc. His prior clinical experience includes clinical development and operations positions at major biotechnology and pharmaceutical companies.
(See Story from BioSpace.com) (10/24/2006)
Acuity Pharmaceuticals Reports Positive Phase II Results For Bevasiranib In Wet AMD
PHILADELPHIA and CANNES, France, Sept. 11 /PRNewswire/ -- Acuity Pharmaceuticals, a clinical stage ophthalmic pharmaceutical company, today announced positive results from its Phase II C.A.R.E(TM) trial for bevasiranib sodium (formerly Cand5), Acuity's lead compound for the treatment of wet age-related macular degeneration (wet AMD). Bevasiranib is a first-in-class small interfering RNA (siRNA) therapeutic designed to silence the genes that produce vascular endothelial growth factor (VEGF), believed to be largely responsible for this leading cause of adult blindness. The findings were presented yesterday at the 24th Annual Meeting of the American Society of Retina Specialists in Cannes, France.
(See Story from BioSpace.com) (09/11/2006)
Acuity Pharmaceuticals And Pathogenics Inc. Announce Preclinical Data Demonstrating Utility Of NCT In Viral Conjunctivitis
PHILADELPHIA and HINGHAM, Mass., Aug. 23 /PRNewswire/ -- Acuity Pharmaceuticals, Inc., a clinical stage ophthalmic pharmaceutical company, and Pathogenics, Inc. today announced publication of preclinical data demonstrating the potential clinical utility of N-Chlorotaurine (NCT) in the treatment of viral conjunctivitis. Acuity recently in-licensed exclusive worldwide development and commercialization rights to a proprietary formulation of NCT for ocular uses from Pathogenics, which is developing NCT for a variety of topical and body cavity infections. The ocular formulation is currently in a Phase I safety study in Europe.
(See Story from BioSpace.com) (08/23/2006)
Acuity Pharmaceuticals Reports Positive Initial Phase II Results For Bevasiranib (Cand5) In Wet AMD
PHILADELPHIA and BALTIMORE, June 1 /PRNewswire/ -- Acuity Pharmaceuticals, an ophthalmic pharmaceutical company, today announced that its lead clinical compound bevasiranib sodium, formerly known as Cand5, appeared safe and showed clinical evidence of efficacy in the first results from the Phase II C.A.R.E.(TM) trial for the treatment of wet AMD. Bevasiranib is a first-in-class small interfering RNA (siRNA) therapeutic designed to turn off or silence the gene that produces VEGF, the growth factor believed largely responsible for wet age-related macular degeneration (wet AMD), a leading cause of adult blindness. The findings are being presented today at the annual meeting of the American Society of Gene Therapy in Baltimore, Maryland.
(See Story from BioSpace.com) (06/01/2006)
ZaBeCor Pharmaceutical Co. Licenses Its Anti-Inflammatory siRNA Technology To Acuity Pharmaceuticals For Ophthalmic Uses
PHILADELPHIA, April 28 /PRNewswire/ -- ZaBeCor Pharmaceutical Co., a privately-held company focused on the development and commercialization of patented drug technology centered on inflammation, today announced that it has entered into a license option agreement with Acuity Pharmaceuticals, a clinical stage, product-focused ophthalmic pharmaceutical company, with Acuity to receive exclusivity for ophthalmologic uses of ZaBeCor's lead drug candidate Excellair(TM). Excellair(TM), an anti-inflammatory small interfering RNA (siRNA), is designed to silence Syk kinase, a key gene associated with inflammation. Excellair(TM) has shown promising activity and safety in preclinical studies for the treatment of asthma and other inflammatory disorders.
(See Story from BioSpace.com) (04/28/2006)
Acuity Pharmaceuticals Continues Pipeline Expansion By Licensing A Novel Broad Spectrum Anti-Infective For Ophthalmic Use
PHILADELPHIA, April 20 /PRNewswire/ -- Acuity Pharmaceuticals, Inc., a clinical stage, product-focused ophthalmic pharmaceutical company, today announced that it has in-licensed exclusive worldwide development and commercialization rights to N-chlorotaurine (NCT), a novel, clinical stage, small molecule agent for the treatment of ophthalmic infections and other conditions. Acuity's lead compound, Cand5, is in clinical trials for wet age- related macular degeneration and diabetic macular edema, and represents the first clinical use of the gene-silencing technology called RNA interference.
(See Story from BioSpace.com) (04/20/2006)
Acuity Pharmaceuticals Completes Patient Enrollment In Phase II Trial In Wet AMD And Initiates New Trial In Diabetic Macular Edema
PHILADELPHIA, Feb. 2 /PRNewswire/ -- Acuity Pharmaceuticals, a product- focused ophthalmic pharmaceutical company, today announced that it has completed the patient dosing component of its Phase II clinical program for Cand5, Acuity's lead product candidate for the treatment of wet age-related macular degeneration (wet AMD), a leading cause of adult blindness. Acuity also announced that it has begun dosing patients in a pilot Phase II trial of Cand5 in its second indication of diabetic macular edema (DME).
(See Story from BioSpace.com) (02/02/2006)
Acuity Pharmaceuticals To Present At Rodman & Renshaw Healthcare Conference
PHILADELPHIA, Nov. 4 /PRNewswire/ -- Acuity Pharmaceuticals, a product-focused ophthalmic pharmaceutical company, today announced that it will present at the Rodman & Renshaw Techvest 7th Annual Healthcare Conference at the New York Palace Hotel in New York City on Tuesday, November 8, 2005 at 4:55pm EST in the Adams Room.
(See Story from BioSpace.com) (11/04/2005)
Acuity Pharmaceuticals Initiates Phase II Trial Of Cand5 In Wet AMD Following Successful Completion Of Phase I
PHILADELPHIA and CHICAGO, Oct. 14 /PRNewswire/ -- Acuity Pharmaceuticals, a product-focused ophthalmic pharmaceutical company, today announced it has initiated its Phase II C.A.R.E(TM) clinical program for Cand5, Acuity's lead product candidate for the treatment of wet age-related macular degeneration (wet AMD), a leading cause of adult blindness. This is the first-ever Phase II program for a small interfering RNA (siRNA) therapy, an innovative approach based on the powerful gene silencing technology of RNA interference (RNAi). Acuity also announced the successful results from its Phase I study showing that Cand5 appears to be safe and well tolerated. These Phase I results are being discussed in three separate presentations at the American Academy of Ophthalmology Annual Meeting in Chicago being held October 14-18, 2005.
(See Story from BioSpace.com) (10/14/2005)
http://www.biospace.com/news_company.aspx?CompanyID=649420
New Website Coming Soon: Acuity Pharmaceuticals and Froptix Corporation Agree to Mergers with Public Shell; New Company to Develop and Market Drugs for Disorders of the Eye http://www.acuitypharma.com/
NITE better be gone tomorrow.he was at the ask all day..
New HOD $3.18 STRONG AT CLOSE.
Thank you and ssp for all the great picks i jumped on at your board (TGL).
Just took out that 0.0075 ASK
Dream you in on EXEG we need someone to bang the table..$3.10
EXEG $3.10 + 23%
RIGHT on time, $4.00 NEXT!!
OVER $3.00 very sone!
just picked up a few more at the ASK 0.008
AMEX Stock Exchange Listing Requirements
Requirements
Standard 1
Standard 2
Standard 3
Shareholders' equity
$4 million
$4 million
$4 million
Pre-tax income
$750,000 in last fiscal year or in two of its last three fiscal years
2 years
$50 million
Distribution
800 public shareholders and 500,000 shares publicly held
OR
400 public shareholders and 1 million shares publicly held
OR
400 public shareholders, 500,000 shares publicly held and average daily trading volume of 2,000 shares for prior 6 months
800 public shareholders and 500,000 shares publicly held
OR
400 public shareholders and 1 million shares publicly held
OR
400 public shareholders, 500,000 shares publicly held and average daily trading volume of 2,000 shares for prior 6 months
800 public shareholders and 500,000 shares publicly held
OR
400 public shareholders and 1 million shares publicly held
OR
400 public shareholders, 500,000 shares publicly held and average daily trading volume of 2,000 shares for prior 6 months
Price
$3
$3
N/A
Market value public float
$3 million
$15 million
$15 million
http://www.venturelawcorp.com/listing_requirements_amex.html
Metal sector set for bumper year
By Gong Zhengzheng (China Daily)
Updated: 2007-03-27 08:43
Non-ferrous metal production in China is expected to grow by 15 percent this year, led by aluminum and copper, boosted by mounting demand, according to an industry organization.
The combined production of 10 main metals aluminum, copper, lead, zinc, nickel, stannum, magnesium, titanium, antimony and mercury will reach 22 million tons in 2007, up from 19.17 million tons last year, said Kang Yi, president of the China Non-ferrous Metal Industry Association.
The 2006 figure made China the world's top non-ferrous metal manufacturer for a fifth consecutive year.
Kang said aluminum production would climb to 11 million tons this year from 9.35 million tons in 2006.
Related readings:
No sign of 'flagging' in copper imports China leads world in nonferrous metals output
Zinc to debut on China's futures exchange next monday
China may cut tin exports by 10% this year
In the meantime, copper production would increase to 3.45 million tons from 3 million tons, he said.
He said China's demand for non-ferrous metals would continue to grow this year thanks to booming metal-consuming industrial sectors such as real estate and cars.
But he didn't provide a specific forecast on demand for this year.
"Prices (of non-ferrous metals) will continue to sway at high levels this year," Kang said.
Last year, prices of many non-ferrous metals such as aluminum, copper, zinc and nickel hit record highs at home and abroad as a result of strong demand and hedge funds buying up metals futures.
Liu Defei, an analyst with Beijing-based metal industry consultancy Antaike Information Development Co Ltd, said domestic aluminum demand would surge by 28 percent to 10.8 million tons this year from 2006.
The growth is up from the 21 percent reported last year, Liu said.
Kang predicted China's production of alumina, the raw material used to make aluminum, would jump to 20 million tons this year from 13.7 million tons in 2006, driven by swelling aluminum production.
http://www.chinadaily.com.cn/bizchina/2007-03/27/content_837080.htm
Sino-Canadian Metals Inc.
YUANSHISHAN
The operation details are shown below:
General location: Ping'an County
Landmark: Xining city (62 km E)
Country: China
Status: Exploration
Minerals: Cobalt, Iron Ore, Nickel
Ownership Information
Yuanshishan is owned by:
Sino-Canadian Metals Inc.
Canada
Cobalt, Iron Ore, Nickel
Qinghai Jiahu Metal Development Co. Ltd.
China
Cobalt, Iron Ore, Nickel
http://www.mqdata.com/data/show_operation.asp?id=1125606504
I am new at all this but it looks to me that, Sino-Canadian Metals Inc.and East Delta Resources Corp. has a joint venture but Sino-Cadadian Metals is a private company looking to become publicly traded, could BIMR be the shell?
Sino-Canadian Metals Inc. is a private Delaware corporation, headquartered in Montreal, Quebec and 63% owned by EDLT. It is the intent of Sino-Canadian Metals to become a publicly traded company in the U.S. within the next 12 months. PR as of 12/1/2006 http://metalsplace.com/metalsnews/?a=8806
Victor Sun, CEO of Sino-Canadian commented, "This an excellent opportunity for realizing a significant find. With nickel prices rising from about $6 per pound to over $15 in the past year, we believe that this acquisition provides tremendous potential for our shareholders."
In EDLT latest PR dated Feb 6, 2007 there primary activity is Gold, but they somewhat seperated EDLT from the other minerals by stating the following:
East Delta Resources Corp. is a publicly traded Delaware corporation, headquartered in Montreal, Quebec whose primary activity is in mine development and production of gold. Through its majority owned subsidiary, Sino Canadian Metals Inc., it also participates in other mineral exploration and mining, specifically, silver, nickel, zinc and lead. The geographic focus of the Companies is China. With funding for current needs in place, majority interest in several highly-prospective properties, experienced personnel, and an extensive network of contacts in China, the Companies are on-track in implementing their business plans and objectives.http://www.primezone.com/newsroom/news.html?d=113209
I've had an etrade order in for 0.0071 with no fill..
FULO up 120% vol 89,500
Mine also show 5 ETRADE
Should he call us each time he wants to make a move in his business?
OUR business! GET IT RIGHT!
Stop blaming them, All they have to go on is what they research.I don't beleave they made anything up, The CEO of a company comes out with a PR how great this company is and going to be, and when pps goes up we get a r/s..this uplisting will do nothing longterm..the company has no money until now from share holders..UPLIST? HAHA, you could bring a BUM to the Taj Mahal he's still a BUM..
Thanks SSP CRDM .17 X .175
Anyone have any thoughts on this? CLEP has been traded all day and there should be no shares out there? Posted by: head22
In reply to: drsilicone who wrote msg# 32 Date:3/21/2007 4:12:49 PM
Post #of 35
The CEO, Dr. Hengst called me and told me that he assumed that the bankruptcy court filed the article 15 he thinks needed to be filed but they must not have. He told me that this was done back in 1994..and the Hemagen liquidated in 1996. He said that Cellular sold all their assets to Hemagen including their name, and it was dissolved. He did say however that the SEC sent him notice that Cellular Products is delinquent on their filings. He said he has some calls into the SEC but they haven't gotten back to him. I had called and left a message and since they had received a number of calls he clled me back cause he didn't want anyone throwing money away at a stock that didn't exist.Nice guy.
How does a stock that doesn't exist still trade...and where does the money go?
Did he say when they sent him notice that Cellular Products is delinquent on their filings?